-
平臺編號：bio-131649
-
細胞信息： KOPN-8
-
規(guī)格：1×10?cells/T25培養(yǎng)瓶
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產品信息以出庫為準）
人B淋巴細胞白血病細胞KOPN-8
細胞名稱：人B淋巴細胞白血病細胞KOPN-8
產品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運輸方式：常溫保溫運輸；干冰運輸
安全等級：1
用途限制：僅供科研3類
培養(yǎng)體系：DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡介：人B淋巴細胞白血病細胞KOPN-8取自女性幼兒外周血，該細胞源于DSMZ
注釋
Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:LL-100 blood cancer cell line panel.
Part of:MD Anderson Cell Lines Project.
Doubling time:~48 hours(DSMZ).
Microsatellite instability:Stable(MSS)(Sanger).
Omics:Deep exome analysis.
Omics:Deep RNAseq analysis.
Omics:DNA methylation analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
Derived from sampling site:Peripheral blood.
基因突變
KMT2A-MLLT1(MLL-MLLT1;MLL-ENL)gene fusion(PubMed=31160637;DSMZ).
Heterozygous for KRAS p.Gly12Asp(c.35G>A)(CCLE;Cosmic-CLP).
Heterozygous for TP53 p.Arg248Gln(c.743G>A)(CCLE;Cosmic-CLP).
HLA信息
/
STR信息
Amelogenin X
CSF1PO 10,12
D5S818 9,11
D7S820 8,10
D13S317 8,11
D16S539 9,11
TH01 6,10
TPOX 8,11
vWA 16,18
參考文獻
PubMed=28196595;DOI=10.1016/j.ccell.2017.01.005
Li J.,Zhao W.,Akbani R.,Liu W.,Ju Z.,Ling S.,Vellano C.P.,Roebuck P.,Yu Q.,Eterovic A.K.,Byers L.A.,Davies M.A.,Deng W.,Gopal Y.N.V.,Chen G.,von Euw E.M.,Slamon D.J.,Conklin D.,Heymach J.V.,Gazdar A.F.,Minna J.D.,Myers J.N.,Lu Y.,Mills G.B.,Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=30285677;DOI=10.1186/s12885-018-4840-5
Tan K.-T.,Ding L.-W.,Sun Q.-Y.,Lao Z.-T.,Chien W.,Ren X.,Xiao J.-F.,Loh X.-Y.,Xu L.,Lill M.,Mayakonda A.,Lin D.-C.,Yang H.,Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940-940(2018)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
PubMed=31068700;DOI=10.1038/s41586-019-1186-3
Ghandi M.,Huang F.W.,Jane-Valbuena J.,Kryukov G.V.,Lo C.C.,McDonald E.R.III,Barretina J.,Gelfand E.T.,Bielski C.M.,Li H.,Hu K.,Andreev-Drakhlin A.Y.,Kim J.,Hess J.M.,Haas B.J.,Aguet F.,Weir B.A.,Rothberg M.V.,Paolella B.R.,Lawrence M.S.,Akbani R.,Lu Y.,Tiv H.L.,Gokhale P.C.,de Weck A.,Mansour A.A.,Oh C.,Shih J.,Hadi K.,Rosen Y.,Bistline J.,Venkatesan K.,Reddy A.,Sonkin D.,Liu M.,Lehar J.,Korn J.M.,Porter D.A.,Jones M.D.,Golji J.,Caponigro G.,Taylor J.E.,Dunning C.M.,Creech A.L.,Warren A.C.,McFarland J.M.,Zamanighomi M.,Kauffmann A.,Stransky N.,Imielinski M.,Maruvka Y.E.,Cherniack A.D.,Tsherniak A.,Vazquez F.,Jaffe J.D.,Lane A.A.,Weinstock D.M.,Johannessen C.M.,Morrissey M.P.,Stegmeier F.,Schlegel R.,Hahn W.C.,Getz G.,Mills G.B.,Boehm J.S.,Golub T.R.,Garraway L.A.,Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31160637;DOI=10.1038/s41598-019-44491-x
Quentmeier H.,Pommerenke C.,Dirks W.G.,Eberth S.,Koeppel M.,MacLeod R.A.F.,Nagel S.,Steube K.,Uphoff C.C.,Drexler H.G.
The LL-100 panel:100 cell lines for blood cancer studies.
Sci.Rep.9:8218-8218(2019)
產品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運輸方式：常溫保溫運輸；干冰運輸
安全等級：1
用途限制：僅供科研3類
培養(yǎng)體系：DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡介：人B淋巴細胞白血病細胞KOPN-8取自女性幼兒外周血，該細胞源于DSMZ
注釋
Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:LL-100 blood cancer cell line panel.
Part of:MD Anderson Cell Lines Project.
Doubling time:~48 hours(DSMZ).
Microsatellite instability:Stable(MSS)(Sanger).
Omics:Deep exome analysis.
Omics:Deep RNAseq analysis.
Omics:DNA methylation analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
Derived from sampling site:Peripheral blood.
基因突變
KMT2A-MLLT1(MLL-MLLT1;MLL-ENL)gene fusion(PubMed=31160637;DSMZ).
Heterozygous for KRAS p.Gly12Asp(c.35G>A)(CCLE;Cosmic-CLP).
Heterozygous for TP53 p.Arg248Gln(c.743G>A)(CCLE;Cosmic-CLP).
HLA信息
/
STR信息
Amelogenin X
CSF1PO 10,12
D5S818 9,11
D7S820 8,10
D13S317 8,11
D16S539 9,11
TH01 6,10
TPOX 8,11
vWA 16,18
參考文獻
PubMed=28196595;DOI=10.1016/j.ccell.2017.01.005
Li J.,Zhao W.,Akbani R.,Liu W.,Ju Z.,Ling S.,Vellano C.P.,Roebuck P.,Yu Q.,Eterovic A.K.,Byers L.A.,Davies M.A.,Deng W.,Gopal Y.N.V.,Chen G.,von Euw E.M.,Slamon D.J.,Conklin D.,Heymach J.V.,Gazdar A.F.,Minna J.D.,Myers J.N.,Lu Y.,Mills G.B.,Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=30285677;DOI=10.1186/s12885-018-4840-5
Tan K.-T.,Ding L.-W.,Sun Q.-Y.,Lao Z.-T.,Chien W.,Ren X.,Xiao J.-F.,Loh X.-Y.,Xu L.,Lill M.,Mayakonda A.,Lin D.-C.,Yang H.,Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940-940(2018)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
PubMed=31068700;DOI=10.1038/s41586-019-1186-3
Ghandi M.,Huang F.W.,Jane-Valbuena J.,Kryukov G.V.,Lo C.C.,McDonald E.R.III,Barretina J.,Gelfand E.T.,Bielski C.M.,Li H.,Hu K.,Andreev-Drakhlin A.Y.,Kim J.,Hess J.M.,Haas B.J.,Aguet F.,Weir B.A.,Rothberg M.V.,Paolella B.R.,Lawrence M.S.,Akbani R.,Lu Y.,Tiv H.L.,Gokhale P.C.,de Weck A.,Mansour A.A.,Oh C.,Shih J.,Hadi K.,Rosen Y.,Bistline J.,Venkatesan K.,Reddy A.,Sonkin D.,Liu M.,Lehar J.,Korn J.M.,Porter D.A.,Jones M.D.,Golji J.,Caponigro G.,Taylor J.E.,Dunning C.M.,Creech A.L.,Warren A.C.,McFarland J.M.,Zamanighomi M.,Kauffmann A.,Stransky N.,Imielinski M.,Maruvka Y.E.,Cherniack A.D.,Tsherniak A.,Vazquez F.,Jaffe J.D.,Lane A.A.,Weinstock D.M.,Johannessen C.M.,Morrissey M.P.,Stegmeier F.,Schlegel R.,Hahn W.C.,Getz G.,Mills G.B.,Boehm J.S.,Golub T.R.,Garraway L.A.,Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31160637;DOI=10.1038/s41598-019-44491-x
Quentmeier H.,Pommerenke C.,Dirks W.G.,Eberth S.,Koeppel M.,MacLeod R.A.F.,Nagel S.,Steube K.,Uphoff C.C.,Drexler H.G.
The LL-100 panel:100 cell lines for blood cancer studies.
Sci.Rep.9:8218-8218(2019)
